Focused On-demand Library for Importin subunit alpha-4

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We use our state-of-the-art dedicated workflow for designing focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

O00505

UPID:

IMA4_HUMAN

Alternative names:

Importin alpha Q2; Karyopherin subunit alpha-3; SRP1-gamma

Alternative UPACC:

O00505; O00191; O43195; Q5JVM9; Q8IYQ9; Q96AA7

Background:

Importin subunit alpha-4, also known as Importin alpha Q2, Karyopherin subunit alpha-3, and SRP1-gamma, plays a crucial role in nuclear protein import. It functions as an adapter protein for nuclear receptor KPNB1, binding directly to substrates with NLS motifs. This process involves docking to the nuclear pore complex, translocation through the pore, and separation of components in the nucleoplasm, facilitated by Ran-dependent mechanisms.

Therapeutic significance:

Importin subunit alpha-4's involvement in Spastic paraplegia 88, autosomal dominant, underscores its potential as a therapeutic target. Understanding its role could open doors to novel strategies for treating this neurodegenerative disorder, characterized by progressive weakness and spasticity of the lower limbs.